Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,714 as of Tuesday, June 3, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,066 issues advancing vs. 1,889 declining with 193 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Humana ( HUM), up 0.8%. Top gainers within the industry include Acadia Healthcare ( ACHC), up 13.7%, Parexel International ( PRXL), up 3.1%, Healthsouth ( HLS), up 2.7%, Grifols ( GRFS), up 1.5% and Omnicare ( OCR), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Centene ( CNC) is one of the companies pushing the Health Services industry lower today. As of noon trading, Centene is down $3.84 (-5.1%) to $71.85 on heavy volume. Thus far, 826,756 shares of Centene exchanged hands as compared to its average daily volume of 633,400 shares. The stock has ranged in price between $71.66-$73.39 after having opened the day at $72.36 as compared to the previous trading day's close of $75.69.

Centene Corporation provides multi-line healthcare programs and services in the United States. It operates in two segments, Managed Care and Specialty Services. Centene has a market cap of $4.3 billion and is part of the health care sector. Shares are up 28.4% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Centene a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Centene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Centene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, CR Bard ( BCR) is down $0.98 (-0.7%) to $147.26 on light volume. Thus far, 253,636 shares of CR Bard exchanged hands as compared to its average daily volume of 796,300 shares. The stock has ranged in price between $147.04-$148.02 after having opened the day at $147.50 as compared to the previous trading day's close of $148.24.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard has a market cap of $11.3 billion and is part of the health care sector. Shares are up 10.7% year-to-date as of the close of trading on Monday. Currently there are 3 analysts that rate CR Bard a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates CR Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CR Bard Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Medtronic ( MDT) is down $0.32 (-0.5%) to $60.70 on light volume. Thus far, 1.5 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $60.48-$60.88 after having opened the day at $60.84 as compared to the previous trading day's close of $61.02.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. Medtronic has a market cap of $61.1 billion and is part of the health care sector. Shares are up 6.3% year-to-date as of the close of trading on Monday. Currently there are 7 analysts that rate Medtronic a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null